FDA approves new use of popular diabetes drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA approves new use of popular diabetes drug" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Drug Topics, Forbes, 10TV and Endpoints News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 75d ago.
Quick answers
Why is "FDA approves new use of popular diabetes drug" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Tirzepatide Receives Expanded Approval for MACE in Patients With T2D Drug Topics · 79d ago
- FDA Approves Mounjaro (Tirzepatide) For Reducing Cardiovascular Risk In Adults with Type 2 Diabetes. Here Are The Best GLP-1 Providers Forbes · 79d ago
- Mounjaro gets FDA approval to lower heart attack, stroke risk in diabetes patients 10TV · 79d ago
- Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug Endpoints News · 79d ago
- FDA approves new use of popular diabetes drug Action News 5 · 79d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche secures United States Food and Drug Administration approval for its new oral breast-cancer pill, Wilserdly.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.